# Amylyx Pharmaceuticals, Inc.: filings

AMLX · Nasdaq · CIK 1658551 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amlx.md) · [Financials](/companies/amlx/financials.md) · [Filings](/companies/amlx/filings.md) · [Insiders](/companies/amlx/insiders.md)

## Reports and events: 87 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 178, 8-K 55, 144 36, 3 17, 10-Q 14, SCHEDULE 13G/A 14, SC 13G 11, SC 13G/A 9, CORRESP 7, SCHEDULE 13G 7, UPLOAD 7, 424B5 6, D 6, S-8 6, 10-K 5, 4/A 5, DEF 14A 5, DEFA14A 5, ARS 4, D/A 4, SC 13D/A 4, EFFECT 3, 3/A 2, 424B4 2, 5 2, DRS 2, DRS/A 2, DRSLTR 2, S-1 2, S-1MEF 2, S-3ASR 2, SEC STAFF LETTER 2, 8-A12B 1, CERT 1, FWP 1, POSASR 1, S-1/A 1, S-3 1, SC 13D 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-08 | 20:54 ET | [8-K](/filings/0001193125-26-385331.md) | 1.01 Entry into a material agreement | 0001193125-26-385331 |
| 2026-08-20 | 21:28 ET | [8-K](/filings/0001193125-26-359418.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-359418 |
| 2026-08-18 | 13:03 ET | [8-K](/filings/0001193125-26-354793.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-354793 |
| 2026-08-18 | 11:09 ET | [8-K](/filings/0001193125-26-354716.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-354716 |
| 2026-08-06 | 11:04 ET | [10-Q](/filings/0001193125-26-336682.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336682 |
| 2026-08-06 | 11:02 ET | [8-K](/filings/0001193125-26-336670.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336670 |
| 2026-06-04 | 20:06 ET | [8-K](/filings/0001193125-26-257390.md) | 5.07 Shareholder vote results | 0001193125-26-257390 |
| 2026-05-07 | 11:04 ET | [10-Q](/filings/0001193125-26-210292.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210292 |
| 2026-05-07 | 11:02 ET | [8-K](/filings/0001193125-26-210286.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210286 |
| 2026-04-23 | 11:01 ET | [DEF 14A](/filings/0001193125-26-171800.md) | Proxy statement, period 2026-06-04 | 0001193125-26-171800 |
| 2026-03-24 | 11:11 ET | [8-K](/filings/0001193125-26-120691.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-120691 |
| 2026-03-03 | 12:10 ET | [10-K](/filings/0001193125-26-086645.md) | Annual report, period 2025-12-31 | 0001193125-26-086645 |
| 2026-03-03 | 12:02 ET | [8-K](/filings/0001193125-26-086629.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-086629 |
| 2026-01-08 | 12:03 ET | [8-K](/filings/0001193125-26-006991.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-006991 |
| 2025-11-06 | 12:11 ET | [10-Q](/filings/0001193125-25-268059.md) | Quarterly report, period 2025-09-30 | 0001193125-25-268059 |
| 2025-11-06 | 12:03 ET | [8-K](/filings/0001193125-25-268043.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-268043 |
| 2025-09-10 | 20:55 ET | [8-K](/filings/0001193125-25-200159.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-200159 |
| 2025-08-27 | 11:05 ET | [8-K](/filings/0001193125-25-189109.md) | 8.01 Other events | 0001193125-25-189109 |
| 2025-08-07 | 11:15 ET | [10-Q](/filings/0001193125-25-174948.md) | Quarterly report, period 2025-06-30 | 0001193125-25-174948 |
| 2025-08-07 | 11:03 ET | [8-K](/filings/0000950170-25-104546.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-104546 |
| 2025-06-05 | 20:04 ET | [8-K](/filings/0001193125-25-135860.md) | 5.07 Shareholder vote results | 0001193125-25-135860 |
| 2025-05-08 | 11:04 ET | [10-Q](/filings/0000950170-25-066363.md) | Quarterly report, period 2025-03-31 | 0000950170-25-066363 |
| 2025-05-08 | 11:01 ET | [8-K](/filings/0000950170-25-066355.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066355 |
| 2025-04-24 | 11:05 ET | [DEF 14A](/filings/0000950170-25-057665.md) | Proxy statement, period 2025-06-05 | 0000950170-25-057665 |
| 2025-03-04 | 11:24 ET | [10-K](/filings/0000950170-25-031309.md) | Annual report, period 2024-12-31 | 0000950170-25-031309 |
| 2025-03-04 | 11:07 ET | [8-K](/filings/0000950170-25-031303.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-031303 |
| 2025-01-10 | 22:23 ET | [8-K](/filings/0001193125-25-004547.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-004547 |
| 2024-12-30 | 12:50 ET | [8-K](/filings/0001193125-24-286212.md) | 7.01 Regulation FD disclosure | 0001193125-24-286212 |
| 2024-11-07 | 13:22 ET | [10-Q](/filings/0000950170-24-122833.md) | Quarterly report, period 2024-09-30 | 0000950170-24-122833 |
| 2024-11-07 | 12:07 ET | [8-K](/filings/0000950170-24-122779.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122779 |
| 2024-10-17 | 13:12 ET | [8-K](/filings/0001193125-24-238572.md) | 8.01 Other events | 0001193125-24-238572 |
| 2024-08-08 | 11:14 ET | [10-Q](/filings/0000950170-24-093311.md) | Quarterly report, period 2024-06-30 | 0000950170-24-093311 |
| 2024-08-08 | 11:09 ET | [8-K](/filings/0000950170-24-093304.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093304 |
| 2024-07-10 | 11:09 ET | [8-K](/filings/0001193125-24-177000.md) | 2.01 Completion of an acquisition or disposition | 0001193125-24-177000 |
| 2024-06-21 | 21:07 ET | [8-K](/filings/0000950170-24-076339.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-076339 |
| 2024-06-06 | 20:07 ET | [8-K](/filings/0001193125-24-156050.md) | 5.07 Shareholder vote results | 0001193125-24-156050 |
| 2024-05-09 | 11:12 ET | [10-Q](/filings/0000950170-24-056269.md) | Quarterly report, period 2024-03-31 | 0000950170-24-056269 |
| 2024-05-09 | 11:05 ET | [8-K](/filings/0000950170-24-056254.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056254 |
| 2024-04-24 | 11:07 ET | [DEF 14A](/filings/0000950170-24-047243.md) | Proxy statement, period 2024-06-06 | 0000950170-24-047243 |
| 2024-04-10 | 13:19 ET | [8-K](/filings/0001193125-24-091463.md) | 8.01 Other events | 0001193125-24-091463 |
| 2024-04-04 | 11:10 ET | [8-K](/filings/0001193125-24-086609.md) | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-086609 |
| 2024-03-14 | 13:18 ET | [8-K](/filings/0001193125-24-067471.md) | 5.02 Departure or appointment of officers or directors | 0001193125-24-067471 |
| 2024-03-08 | 12:10 ET | [8-K](/filings/0001193125-24-062878.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-062878 |
| 2024-02-22 | 13:22 ET | [10-K](/filings/0000950170-24-018447.md) | Annual report, period 2023-12-31 | 0000950170-24-018447 |
| 2024-02-22 | 12:08 ET | [8-K](/filings/0000950170-24-018409.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-018409 |
| 2023-12-07 | 12:00 ET | [8-K](/filings/0001193125-23-290302.md) | 7.01 Regulation FD disclosure | 0001193125-23-290302 |
| 2023-11-09 | 12:07 ET | [10-Q](/filings/0000950170-23-061516.md) | Quarterly report, period 2023-09-30 | 0000950170-23-061516 |
| 2023-11-09 | 11:58 ET | [8-K](/filings/0000950170-23-061505.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-061505 |
| 2023-10-13 | 21:20 ET | [8-K](/filings/0001193125-23-256178.md) | 8.01 Other events | 0001193125-23-256178 |
| 2023-10-04 | 20:19 ET | [SC 13D/A](/filings/0001193125-23-250741.md) | Ownership report, active investor, amended | 0001193125-23-250741 |

Page 1 of 2. [Older](/companies/amlx/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.